Mostrar el registro sencillo del ítem

Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets

dc.contributor.authorGhanaatian N.
dc.contributor.authorLashgari N.-A.
dc.contributor.authorAbdolghaffari A.H.
dc.contributor.authorRajaee S.M.
dc.contributor.authorPanahi Y.
dc.contributor.authorBarreto G.E.
dc.contributor.authorButler A.E.
dc.contributor.authorSahebkar A.
dc.date.accessioned2020-09-02T22:19:21Z
dc.date.available2020-09-02T22:19:21Z
dc.date.issued2019
dc.identifier10.1002/jcp.27965
dc.identifier.citation234, 8, 12237-12248
dc.identifier.issn00219541
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4715
dc.descriptionMultiple sclerosis (MS) is a disease that has shown a considerable increase in prevalence in recent centuries. Current knowledge about its etiology is incomplete, and therefore it cannot be managed optimally utilizing targeted therapeutic regimens at each stage of the disease. MS progresses in different stages, beginning with a cascade of inflammation. The pivotal spark to initiate this cascade seems to be the migration of Th17 into the central nervous system across the blood–brain barrier (BBB) through the disrupted tight junctions. Coupling of interleukin (IL)-17 and IL-22 to their receptors in the BBB layer facilitates this migration. Subsequently, axon degeneration and the various manifestations of nerve–muscle disorders appear. Curcumin, a major component of turmeric, is derived from Curcuma longa, which belongs to the Zingiberaceae family. Numerous properties of curcumin have been identified recently, some of which can be effective in the treatment of MS, particularly the anti-inflammatory properties via inhibition of secretion of proinflammatory cytokines. In this paper, we will review the various properties and key effects of curcumin for the treatment of MS. © 2018 Wiley Periodicals, Inc.
dc.language.isoen
dc.publisherWiley-Liss Inc.
dc.subjectcurcumin
dc.subjectimmune system
dc.subjectinflammation
dc.subjectmultiple sclerosis (MS)
dc.subjectcurcumin
dc.subjectinterleukin 1
dc.subjectinterleukin 17
dc.subjectinterleukin 22
dc.subjectinterleukin 6
dc.subjectinterleukin 8
dc.subjectmacrophage inflammatory protein 2
dc.subjectantiinflammatory agent
dc.subjectcurcumin
dc.subjectcytokine
dc.subjectplant extract
dc.subjectturmeric extract
dc.subjectantiinflammatory activity
dc.subjectblood brain barrier
dc.subjectcalcium cell level
dc.subjectCD4+ T lymphocyte
dc.subjectcell adhesion
dc.subjectcell differentiation
dc.subjectcell migration
dc.subjectCurcuma longa
dc.subjectcytokine production
dc.subjectdrug bioavailability
dc.subjectdrug delivery system
dc.subjectdrug mechanism
dc.subjectdrug metabolism
dc.subjecthuman
dc.subjectimmune response
dc.subjectimmunocompetent cell
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectmicroemulsion
dc.subjectmicroencapsulation
dc.subjectmultiple sclerosis
dc.subjectnerve fiber degeneration
dc.subjectnonhuman
dc.subjectpolymerization
dc.subjectprevalence
dc.subjectpriority journal
dc.subjectregulatory T lymphocyte
dc.subjectReview
dc.subjectTh17 cell
dc.subjecttight junction
dc.subjectanimal
dc.subjectchemistry
dc.subjectCurcuma
dc.subjectinflammation
dc.subjectmetabolism
dc.subjectmultiple sclerosis
dc.subjectAnimals
dc.subjectAnti-Inflammatory Agents
dc.subjectCurcuma
dc.subjectCurcumin
dc.subjectCytokines
dc.subjectHumans
dc.subjectInflammation
dc.subjectMultiple Sclerosis
dc.subjectPlant Extracts
dc.titleCurcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85058157855.pdf
Tamaño:
3.901Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem